

1 **TITLE:** The emergence of SARS-CoV-2 lineages and associated antibody responses among  
2 asymptomatic individuals in a large university community

3  
4 **AUTHORS & AFFILIATIONS:** Marlena R. Merling <sup>1</sup>, Amanda Williams <sup>1,2</sup>, Najmus Mahfooz <sup>1</sup>,  
5 Marisa Ruane-Foster <sup>1</sup>, Jacob Smith <sup>2</sup>, Jeff Jahnes <sup>2</sup>, Leona W. Ayers <sup>3</sup>, Jose A. Bazan <sup>4</sup>, Alison  
6 Norris <sup>4,5</sup>, Abigail Norris Turner <sup>4</sup>, Michael Oglesbee <sup>2</sup>, Seth A. Faith <sup>2</sup>, Mikkel B. Quam <sup>5, \*</sup>, Richard  
7 T. Robinson<sup>1, \*</sup>

8  
9 <sup>1</sup> Department of Microbial Infection & Immunity, The Ohio State University, Columbus, OH, USA

10 <sup>2</sup> Infectious Disease Institute, The Ohio State University, Columbus, OH, USA

11 <sup>3</sup>Department of Pathology, The Ohio State University, Columbus, OH, USA

12 <sup>4</sup> Division of Infectious Disease, Department of Internal Medicine, The Ohio State University,  
13 Columbus, OH, USA

14 <sup>5</sup>Department of Epidemiology, The Ohio State University, Columbus, OH, USA

15 \* Co-corresponding authors

16 **ABSTRACT**

17 SARS-CoV-2 (CoV2) infected, asymptomatic individuals are an important contributor to COVID  
18 transmission. CoV2-specific immunoglobulin (Ig)—as generated by the immune system following  
19 infection or vaccination—has helped limit CoV2 transmission from asymptomatic individuals to  
20 susceptible populations (e.g. elderly). Here, we describe the relationships between COVID  
21 incidence and CoV2 lineage, viral load, saliva Ig levels (CoV2-specific IgM, IgA and IgG) and  
22 inhibitory capacity in asymptomatic individuals between Jan 2021 and May 2022. These data  
23 were generated as part of a large university COVID monitoring program and demonstrate that  
24 COVID incidence among asymptomatic individuals occurred in waves which mirrored those in  
25 surrounding regions, with saliva CoV2 viral loads becoming progressively higher in our community  
26 until vaccine mandates were established. Among the unvaccinated, infection with each CoV2  
27 lineage (pre-Omicron) resulted in saliva Spike-specific IgM, IgA and IgG responses, the latter  
28 increasing significantly post-infection and being more pronounced than N-specific IgG responses.  
29 Vaccination resulted in significantly higher Spike-specific IgG levels compared to unvaccinated  
30 infected individuals, and uninfected vaccinees' saliva was more capable of inhibiting Spike  
31 function. Vaccinees with breakthrough Delta infections had Spike-specific IgG levels comparable  
32 to those of uninfected vaccinees; however, their ability to inhibit Spike binding was diminished.  
33 These data demonstrate that COVID vaccines achieved hoped-for effects in our community,  
34 including the generation of mucosal antibodies that inhibit Spike and lower community viral loads,  
35 and suggest breakthrough Delta infections were not due to an absence of vaccine-elicited Ig, but  
36 instead limited Spike binding activity in the face of high community viral loads.

## 37 INTRODUCTION

38 Coronaviruses are single-stranded RNA viruses that cause respiratory disease in a range of  
39 mammalian hosts. The Coronavirus Disease 2019 (COVID-19, or COVID) pandemic began in  
40 December 2019, after transmission of a novel coronavirus to an individual living in China. The  
41 sequence homology of this novel coronavirus to severe acute respiratory syndrome associated  
42 coronavirus (SARS-CoV) led to its being named SARS-CoV-2 (CoV2). CoV2 spreads via aerosol  
43 and respiratory droplets, causing either an asymptomatic infection or a flu-like illness that affects  
44 multiple organ systems and presents as fever, cough, dyspnea, malaise, delirium and death.  
45 International spread of CoV2 was rapid, and by February 2020 it had spread to nearly every  
46 country in the world (1). Now, 3 years after its emergence, CoV2 is estimated to have infected  
47 ~630 million individuals and killed >6.5 million individuals worldwide (2). The United States has  
48 reported more deaths than any other country (2).

49  
50 Viruses mutate to varying degrees depending on the nature of their genome and the proofreading  
51 activity (or lack thereof) of associated polymerases. CoV2 is no exception to this, and within a  
52 year of its emergence multiple lineage variants of concern (VOCs) appeared in numerous  
53 countries. B.1.1.7 (now called Alpha) and B.1.351 (now called Beta) were the first VOCs to be  
54 identified in September 2020 (Alpha, in United Kingdom) and October 2020 (Beta, in South  
55 Africa), and contained numerous missense mutations affecting the Spike protein (3, 4). The Spike  
56 protein is essential for CoV2 infection of target cells and contains a receptor-binding domain  
57 (RBD) which recognizes and binds the host receptor angiotensin-converting enzyme 2 (ACE2)  
58 (5). The Alpha and Beta lineage RBD mutations lead to tighter Spike:ACE2 structural interactions  
59 (6) and increased the transmissibility of CoV2 (7, 8). In January 2021, the P.1. (now called  
60 Gamma) lineage was reported in Brazil to contain even more missense mutations in more genes,  
61 including Spike (9). As with Alpha, the mutations inherent to the Gamma lineage increased its  
62 transmissibility (9). Two additional lineages emerged in March 2021 and November 2021,

63 respectively, and in time would supplant all prior lineages in the speed with which they spread:  
64 the Delta lineage, which was first reported in India (10), and the Omicron lineage, reported in  
65 southern Africa (11). CoV2 continues to evolve, and deaths due to COVID continue to cause  
66 overall declines in life expectancy for many countries, including the United States (12, 13).

67  
68 After previous coronavirus disease outbreaks, such as those caused by SARS-CoV and Middle  
69 East respiratory syndrome coronavirus (MERS-CoV), animal models and other experimental  
70 systems demonstrated that coronavirus-specific antibodies are generated soon after infection (14,  
71 15), and can block viral entry by interfering with the Spike:ACE2 interaction (16-21). In the upper  
72 respiratory tract and oral cavity, antibodies are generated by B cells in mucosa-associated  
73 lymphoid tissue (MALT) and regional draining lymph nodes, typically within several days of  
74 antigen encounter, and comprise several isotypes (IgM, IgA and IgG) which differ in their secretion  
75 kinetics and effector mechanism. IgM is often the first isotype to appear following antigen  
76 exposure, and eliminates viruses by precipitating the membrane attack complex on virus-infected  
77 cells (i.e. the classical complement pathway). In the context of CoV2 infection, however, IgA  
78 dominates the early neutralizing antibody response at mucosal sites (22). IgA, a weak inducer of  
79 the complement pathway, protects mucosal sites by blocking and sterically hindering antigen  
80 interaction with the epithelial surface, trapping it in mucus which is eventually cleared via  
81 peristalsis. IgG is often the last isotype to appear following antigen exposure but is the most  
82 versatile in terms of effector mechanisms and durability, as the B cells which produce IgG can  
83 become plasma cells that reside in bone marrow and continuously secrete IgG for months to  
84 years.

85  
86 The fact that coronavirus-specific Ig is secreted following natural infection, long-lived, and able to  
87 disrupt Spike:ACE2 interactions are the foundations on which multiple monitoring, therapeutic  
88 and vaccine strategies against CoV2 have been built. Prior to mass PCR testing, CoV2-reactive



89 Ig in sera was the only biomarker for monitoring CoV2 prevalence at a population level (23). The  
90 discovery that plasma of COVID-convalescent individuals contains polyclonal Ig with CoV2-  
91 neutralizing activity (24) paved the way for multiple clinical trials testing the efficacy of  
92 convalescent plasma therapy against COVID (25). Whether convalescent plasma therapy was  
93 efficacious remains debated (26). What is not debated, however, is the efficacy of vaccines which  
94 were designed to elicit Ig against CoV2. In the US, the first COVID vaccines available comprised  
95 either a two-dose encapsulated mRNA formulation (BNT162b2 or mRNA-1273) or a single-dose  
96 adenovirus vector formulation (Ad26.COV2.S). The US Food & Drug Administration (FDA)  
97 granted emergency use authorizations (EUA) for BNT162b2 and mRNA-1273 on Dec 11 2020  
98 and Dec 18 2020, respectively (27, 28); the FDA EUA for Ad26.COV2.S was granted on Feb 27  
99 2021 (29). The advent of these and other COVID vaccines led to dramatic declines in COVID  
100 morbidity and mortality (30), and—relative to vaccinated individuals—unvaccinated individuals  
101 are more likely to need hospitalization or die following CoV2 infection (31).

102  
103 Since interrupting the Spike:ACE2 interaction was the goal of now-approved vaccines (32, 33),  
104 and remains a goal of potential COVID therapies (34, 35), the continual emergence of new CoV2  
105 lineages with numerous and diverse Spike mutations threatens our ability to prevent and treat  
106 future CoV2 infections. It is therefore important to understand the relationships between CoV2  
107 lineage emergence, CoV2-specific Ig levels—as elicited by either natural infection or  
108 vaccination—and their neutralization capacity. This is especially true of asymptomatic individuals  
109 who are PCR positive (PCR<sup>POS</sup>), as they are estimated to account for 50-65% of all transmission  
110 (36, 37). Here, we describe the relationships between COVID incidence, CoV2 lineage, viral load,  
111 CoV2-specific Ig responses (IgM, IgA & IgG) and inhibitory capacity in the saliva of asymptomatic  
112 PCR<sup>POS</sup> individuals, as the oral cavity and saliva—in addition to being readily accessible—are  
113 important sites of CoV2 infection and transmission (38) (especially newer Omicron variants (39-  
114 43)). CoV2-specific Ig responses were similarly assessed in PCR<sup>NEG</sup> individuals with a history of

115 CoV2 infection and/or COVID vaccination with pre-Omicron vaccines. These data were generated  
116 as part of a large university COVID monitoring program which occurred between Aug 2020 → Jun  
117 2022.

118 **METHODS**

119

120 **Institutional approval statement.** This work was reviewed and approved by The Ohio State  
121 University Biomedical Sciences Institutional Review Board (ID #2021H0080). This work was also  
122 reviewed and approved by the Ohio State Institutional Biosafety Committee (IBC) (ID  
123 #2020R00000046).

124

125 **Saliva specimen collection and handling.** The Ohio State COVID monitoring program was  
126 active from Aug 2020 through June 2022. As part of this program, saliva specimens were collected  
127 on a weekly basis from students, staff and faculty who self-reported as being asymptomatic at the  
128 time of specimen collection. On and prior to the day of saliva collection at one of several mass  
129 testing sites (**FIG 1A**), individuals were instructed to define themselves *symptomatic* if they had  
130 at least one or more of the following : fever, chills, shortness of breath, difficulty breathing, fatigue,  
131 muscle aches, body aches, headache, new loss of taste, new loss of smell, sore throat,  
132 congestion, runny nose, nausea, vomiting, or diarrhea. To prevent contagion, symptomatic  
133 individuals were instructed not to come to the mass testing site and were instead referred to a  
134 healthcare provider for follow-up (e.g. the campus student health clinic). Individuals were defined  
135 as *asymptomatic* if they had none of the symptomatic conditions listed above. On the day of  
136 testing, individuals were instructed to refrain from food or drink for 30 minutes prior to collection,  
137 and to gently eject saliva into the collection tube, swallowing first and keeping saliva free from  
138 mucus, until the 1 mL mark on a sterile conical was reached (i.e. passive drool method).  
139 Specimens from asymptomatic individuals were collected at each of the six Ohio State campuses  
140 in Franklin county (OSU-Columbus), Licking county (OSU-Newark), Richland county (OSU-  
141 Mansfield), Allen county (OSU-Lima), Marion county (OSU-Marion) and Wayne county (OSU-  
142 Wooster). Specimens were then couriered to the CLIA-approved Applied Microbiology Services  
143 Lab (AMSL) of the Ohio State Infectious Disease Institute (IDI) and analyzed in accordance with

144 the SalivaDirect assay, a clinical diagnostic test that is Emergency Use Authorization (EUA)  
145 approved by the US Food & Drug Administration (FDA) for SARS-COV-2 detection (44). While  
146 performing the SalivaDirect real time polymerase chain reaction (PCR), saliva samples were  
147 stored in a 4°C cold room until they were deemed either PCR negative (PCR<sup>NEG</sup>) or PCR positive  
148 (PCR<sup>POS</sup>) for CoV2. Per the SalivaDirect method (45), any sample with a C<sub>T</sub> value ≤ 40 was  
149 considered PCR<sup>POS</sup> for CoV2. The positive or negative status of the sample was reported to the  
150 individual and regional public health authorities (Columbus Public Health, Ohio Department of  
151 Health, ODH, ) per state and federal policies at the time. PCR<sup>POS</sup> saliva samples and select  
152 PCR<sup>NEG</sup> saliva samples were then removed from the 4°C cold room, aliquoted into microcentrifuge  
153 tubes, frozen (-20°C) and analyzed for viral genome sequencing and lineage identification, as  
154 well as host antibody response characterization.

155

156 **Sequencing and Lineage Identification:** PCR<sup>POS</sup> saliva samples with a C<sub>T</sub> ≤ 33 had their whole  
157 CoV2 viral genome sequenced and lineage assigned per the methods described in our previous  
158 work (46) (samples with a C<sub>T</sub> > 33 had insufficient viral RNA for sequencing). CoV2 genome copy  
159 numbers were calculated via linear regression analysis, by comparison to the C<sub>T</sub> values of  
160 SalivaDirect reference standards. CoV2 genome sequences were submitted to the Global  
161 Initiative on Sharing Avian Influenza Data (GISAID) database in a manner consistent with ODH  
162 expectations and policies at that time, in as close to real time as possible. The abbreviations we  
163 use for each lineage in this study and associated figures are as follows: CoV2<sup>Anc</sup>, the ancestral  
164 lineage of CoV2 which emerged from Wuhan, China; CoV2<sup>US</sup>, the B.1.2 lineage which was among  
165 the first detected in our region of the United States (46-48); CoV2<sup>Alpha</sup>, the B.1.1.7 lineage or Alpha  
166 variant of concern (VOC) which was first reported by the UK in Dec 2020 (3); CoV2<sup>Beta</sup>, the B.1.351  
167 lineage or Beta VOC which was first reported in South Africa in Dec 2020 (4); CoV2<sup>Gamma</sup>, the P.1  
168 lineage or Gamma VOC which was first reported in Brazil in Jan 2021 (9); CoV2<sup>Delta</sup>, the B.1.617.2

169 lineage or Delta VOC which was first reported in India in Dec 2020 (10); CoV2<sup>Omicron</sup>, the  
170 B.1.1.529 lineage or Omicron VOC which was first reported in South Africa in Nov 2021 (11);  
171 CoV2<sup>O-BA.1</sup>, the BA.1 variant of CoV2<sup>Omicron</sup>; CoV2<sup>O-BA.2</sup>, the BA.2 variant of CoV2<sup>Omicron</sup>; CoV2<sup>O-BA.4</sup>,  
172 the BA.4 variant of CoV2<sup>Omicron</sup>; CoV2<sup>O-BA.5</sup>, the BA.2 variant of CoV2<sup>Omicron</sup>. The nonsynonymous  
173 Spike mutations which distinguish these lineages are depicted in supplemental **FIG S1**. Any  
174 lineage which was not a VOC or otherwise not mentioned above (e.g. Epsilon) is labeled “Non-  
175 VOC.”

176  
177 **COVID wave designations and comparisons.** We defined a COVID wave within our university  
178 community as when new PCR<sup>POS</sup> case counts rose above the overall period median for  $\geq 3$  weeks  
179 in a row (the overall period being Jan 2021 through Jun 2022). For comparisons to COVID  
180 incidence in surrounding counties, we accessed publicly available ODH data via their public-  
181 facing dashboard (accessed Nov 14 2022).

182  
183 **Measuring Binding Antibody Levels in Saliva:** After PCR results were reported (typically within  
184 24 hours of specimen collection), PCR<sup>POS</sup> and select PCR<sup>NEG</sup> specimens were removed from the  
185 4°C cold room, aliquoted into microcentrifuge tubes containing Triton X-100 to inactivate CoV2  
186 (final concentration: 1% Triton X-100) (49). PCR<sup>NEG</sup> samples were selected based on the donors’  
187 having had either a prior CoV2 infection (allowing us to measure durability of the antibody  
188 response following natural infection) or their having been vaccinated against COVID (allowing us  
189 to compare the antibody responses of uninfected vaccinated individuals to those of infected  
190 vaccinated individuals, a.k.a. breakthrough infections). All samples were treated identically  
191 regardless of whether they were PCR<sup>POS</sup> or PCR<sup>NEG</sup>. Following the addition of Triton X-100,  
192 samples were vortexed and allowed to incubate for 1 hour at room temperature (49). Samples  
193 were subsequently stored at -80°C until the antibody levels in all samples could be measured at  
194 the same time, thus eliminating batch effects. The Meso Scale Diagnostics (MSD) V-Plex platform

195 was used to measure the concentration of CoV2 antigen specific immunoglobulin (IgM, IgA and/or  
196 IgG) in PCR<sup>POS</sup> and PCR<sup>NEG</sup> samples. Briefly, the MSD V-Plex assay comprises a 96-well plate  
197 which, within each well, contains multiple spots that were coated with defined antigens. For our  
198 study, these antigens included recombinant forms of three CoV2<sup>Anc</sup> lineage proteins  
199 (Nucleocapsid [N], Spike, and the Spike Receptor Binding Domain [RBD]), as well as CoV2<sup>Alpha</sup>  
200 Spike, CoV2<sup>Beta</sup> Spike, CoV2<sup>Gamma</sup> Spike, and CoV2<sup>Delta</sup> Spike (**FIG S1**). The Spike antigens  
201 consisted of the trimerized form of the ectodomain; the N antigen consisted of the full-length  
202 protein. Antibodies in the sample bind to the antigens, and reporter-conjugated secondary  
203 antibodies were used for detection. Saliva samples were thawed on ice and diluted by a factor of  
204 10 in the diluent provided in the V-Plex assay kit for each assay. The V-Plex assays were  
205 performed according to manufacturer instructions, and plates were read on an MSD instrument  
206 which measures light emitted from reporter-conjugated secondary antibodies. Using MSD's  
207 analysis software, the light signal measured by the MSD instrument was converted into arbitrary  
208 units (AU) representing amount of antibody present relative to the standard curve of the assay.  
209 The AU values for IgM, IgA and IgG binding to CoV2<sup>Anc</sup> N, Spike, and Spike RBD were  
210 transformed to WHO binding antibody units (BAU) via validated WHO standards and conversion  
211 factors provided by MSD. The AU values for IgM, IgA and IgG binding to other forms of N or Spike  
212 (i.e., those of VOC) cannot be converted to WHO BAU, as there are no WHO standards for these  
213 recombinant proteins. For this reason, the levels of each Ig isotype which bind to CoV2<sup>Alpha</sup>,  
214 CoV2<sup>Beta</sup>, CoV2<sup>Gamma</sup>, and CoV2<sup>Delta</sup> forms of Spike are expressed as AU.

215  
216 **Spike inhibition assay.** The capacity of saliva specimens to inhibit Spike activity was quantified  
217 using a commercially available ACE2 displacement assay (MSD COVID-19 ACE2 Neutralization  
218 Kit method). Plate-bound Spike was incubated with diluted saliva (the same specimens used for  
219 Ig measurements) per manufacturer protocols, followed by washing and addition of a luminescent  
220 probe-conjugated, recombinant form of human ACE2. The extent to which luminescence declined

221 relative to non-saliva (i.e., diluent only) treated wells was used to derive a percent inhibition value  
222 for each individual sample, using the following formula: % inhibition =  $1 - (\text{saliva sample}$   
223  $\text{luminescence value} / \text{diluent only luminescence value}) \times 100$ .

224  
225 **Graphing and statistics.** Graphs were generated in RStudio or GraphPad. All statistical tests  
226 were performed in RStudio. Data was tested for normality using the Kolmogorov-Smirnov test and  
227 for equal variance using the Bartlett test of homogeneity of variances. For data that did not have  
228 normal distribution, the Kruskal-Wallis rank sum test was used to determine if there were  
229 significant differences between groups in unpaired datasets, and the Friedman rank sum test was  
230 used in paired datasets. Within those datasets, the significant differences between groups were  
231 identified via an unpaired or paired Wilcoxon rank sum test as appropriate with Benjamini-  
232 Hochberg p value adjustment method. For the neutralization data which contained several zero  
233 values, the Shapiro-Wilk normality test was used, followed by the Bartlett test of homogeneity of  
234 variances. The Kruskal-Wallis rank sum test was used to determine if significant differences were  
235 present, followed by Dunn's test with Benjamini-Hochberg p value adjustment method to identify  
236 which groups were significantly different. Differences between groups were considered significant  
237 if  $P < 0.05$  and are graphically indicated by 1 or more asterisks ( $*P < 0.05$ ;  $**P < 0.005$ ;  $***P <$   
238  $0.0005$ ).

239  
240 **Abbreviations.** The following abbreviations are used throughout our manuscript: **PCR<sup>POS</sup>**, an  
241 individual or saliva specimen that was PCR positive for CoV2 ( $C_T$  value  $\leq 40$ ) ; **PCR<sup>NEG</sup>**, an  
242 individual or saliva specimen that was PCR negative for CoV2; **Spike** and **N**, unless otherwise  
243 stated the Spike and N proteins of CoV2 (not any other coronavirus); **CoV2-Ig**, immunoglobulin  
244 of any isotype that recognizes any CoV2 antigen; **IgM<sup>Spike</sup>**, IgM that recognizes Spike; **IgA<sup>Spike</sup>**,  
245 IgA that recognizes Spike; **IgG<sup>Spike</sup>**, IgG that recognizes Spike; **IgG<sup>RBD</sup>**, IgG that recognizes the

246 Spike Receptor Binding Domain; **IgG<sup>N</sup>**, IgG that recognizes the N protein; **Vax<sup>POS</sup>**, an individual  
247 who was fully vaccinated against COVID (but not boosted) prior to saliva specimen collection;  
248 **Vax<sup>NEG</sup>**, an individual who was not fully vaccinated against COVID prior to saliva specimen  
249 collection; **New<sup>POS</sup>**, an individual who at the time of saliva collection was PCR<sup>POS</sup> for the first time;  
250 **Prior<sup>POS</sup>**, an individual who at the time of saliva collection was PCR<sup>NEG</sup> but who had a prior CoV2  
251 infection (i.e. the individual had been PCR<sup>POS</sup> 3-9 months prior).



## 252 RESULTS

253

### 254 I. Study overview

255

256 The first confirmed cases of COVID in the state of Ohio were reported on Mar 9 2020 (50). The  
257 Ohio State University suspended on campus activities the same day (51) and subsequently  
258 developed a campus wide plan to monitor the incidence of CoV2 infection among its students,  
259 staff and faculty (52). Individuals participating in this monitoring program, which formally began in  
260 Aug 2020, provided saliva on a weekly basis for COVID testing. Prior to testing, individuals who  
261 self-reported as being symptomatic were not tested and were instead given a clinical referral (see  
262 *Methods* for additional details). Individuals who self-reported as being asymptomatic provided a  
263 saliva specimen via a passive drool method at each of our six university campuses (**FIG 1A**).  
264 Specimens were assessed by our CLIA-certified lab for the presence of CoV2 using real-time  
265 quantitative reverse transcription PCR (qRT-PCR). Specimens were not pooled prior to testing.  
266 qRT-PCR results were reported to the individual and the regional public health authority per state  
267 and federal policies at the time. If a specimen had a  $C_T$  value  $\leq 40$  it was considered positive for  
268 CoV2 virus (PCR<sup>POS</sup>). Per our Institutional Review Board (IRB) approved protocols and workflows  
269 (**FIG 1B**), PCR<sup>POS</sup> saliva samples were subsequently used for CoV2 lineage identification and  
270 CoV2-specific immunoglobulin (CoV2-Ig) measurements. In some instances, select saliva  
271 samples that were negative for CoV2 virus (PCR<sup>NEG</sup>) were also collected, the reasons for which  
272 will be made clear in sections below. The relationships between these molecular and  
273 immunological readouts to one another, as well as to coded data concerning the prior infection  
274 status and vaccination status of the saliva donor, are described below for the period spanning Jan  
275 2021 (before COVID vaccines were widely available to students in our university community) to  
276 June 2022, when the monitoring program ended. See *Methods* for details regarding saliva  
277 collection, symptomatic versus asymptomatic designation, qRT-PCR, CoV2 lineage identification,

278 CoV2-Ig measurements, and statistical analyses. In total, >850,000 diagnostic PCR tests were  
279 performed by our lab during this monitoring program.

280

281 **II. The incidence of CoV2 positivity in our university community occurred in waves which**  
282 **reflected those occurring in surrounding regions.**

283

284 The incidence of new PCR<sup>POS</sup> cases among asymptomatic individuals in our university  
285 community, for the period spanning Jan 2021→June 2022, is shown in **FIG 2**. COVID monitoring  
286 occurred before Jan 2021; however, because the bulk of PCR testing at that time was contracted  
287 to a commercial entity, our access to the raw PCR data before Jan 2021 is limited. Above these  
288 data are two timelines relevant to data interpretation, indicating when Ohio COVID vaccination  
289 policies shifted from prioritizing at risk populations (e.g. elderly) to anyone ≥16 years of ages well  
290 as the deadlines for all our community members (i.e. university students, faculty and staff) to have  
291 received their first and second COVID doses (Oct 15 2021 and Nov 15 2021, respectively) (53).  
292 Indicated below the data are corresponding intervals in the academic calendar, which will be  
293 referred to in subsequent sections. We identified 11,989 PCR<sup>POS</sup> individuals between Jan  
294 2021→June 2022; the median, mean and maximum new PCR<sup>POS</sup> cases per test day were 15, 34  
295 and 523, respectively. There were, however, six time periods when the new case counts rose  
296 above the overall period median for ≥ 3 weeks in a row. These six time periods are hereafter  
297 referred to as Waves 1–6 and spanned the following dates: *Wave 1*, Jan 11 2021→ Jan 29 2021;  
298 *Wave 2*, Feb 22 2021→ Mar 12 2021; *Wave 3*, Mar 22 2021→ Apr 16 2021; *Wave 4*, Aug 16  
299 2021→ Sep 24 2021; *Wave 5*, Nov 15 2021→ Feb 18 2022; *Wave 6*, Apr 18 2022→ May 6 2022.  
300 The waves of COVID incidence amongst asymptomatic individuals in our university community  
301 mirrored (rather than preceded) the waves of COVID incidence in the counties surrounding each  
302 university campus (54) (supplemental **FIG S2**).

303

304 **III. Prior to community vaccine requirements being established, CoV2 was becoming**  
305 **progressively more concentrated in the saliva of asymptomatic individuals.**

306

307 The emergence of CoV2 lineage variants in multiple Ohio communities (55-61) with potential for  
308 greater infectivity and/or transmissibility led us to assess the relationship between CoV2  
309 abundance in saliva and variant identity. We used the qRT-PCR cycle threshold ( $C_T$ ) value as a  
310 readout of CoV2 abundance, as the SalivaDirect  $C_T$  value is inversely proportional to CoV2 viral  
311 load (i.e. a lower  $C_T$  value corresponds to higher CoV2 RNA levels in the tested sample) (45), and  
312 a commonly used as a proxy for probability of transmission (i.e. a lower  $C_T$  value correspond to  
313 higher transmission probability) (62-66). Variant identity was determined by next generation  
314 sequencing of the entire CoV2 genome and subsequent alignment with Global Initiative on  
315 Sharing Avian Influenza Data (GISAID) reference sequences. During the entire monitoring period,  
316 CoV2 genome sequences were submitted to the GISAID database in a manner consistent with  
317 ODH expectations and policies at that time, in as close to real time as possible.

318

319 The weekly composite and daily individual  $C_T$  values of each PCR<sup>POS</sup> individual over this period  
320 are shown in **FIG 3A** and **FIG 3B**, respectively, with color annotations in **FIG 3B** indicating the  
321 lineage identity. The same data are presented in two ways (weekly composite versus daily  
322 individual) in order to best illustrate the following trends: During Wave 1 (Week 2 of Jan 2021 →  
323 Week 4 of Jan 2021), the median weekly  $C_T$  values of all PCR<sup>POS</sup> saliva samples ranged between  
324 29 - 30.5 (**FIG 3A**). During Wave 2 (Week 4 of Feb 2021 → Week 2 of Mar 2021) the median  
325 weekly  $C_T$  values ranged between 28 - 30.5 (**FIG 3A**). The median  $C_T$  range lowered and tightened  
326 during Wave 3 (Week 4 of Mar 2021 → Week 2 of Apr 2021) median weekly  $C_T$  values ranged  
327 from 28.5 - 29.5 (**FIG 3A**). The number of tests performed fell precipitously during Jun 2021 and

328 Jul 2021, as the campus population is minimal during the summer months; therefore, we are  
329 reluctant to draw conclusions from or otherwise compare Summer 2021  $C_T$  value data to the prior  
330 semester, when testing volume was higher. Upon resumption of high-volume testing during the  
331 later weeks of August 2021, which marked the beginning of the Autumn 2021 semester and Wave  
332 4 (Week 3 of Aug 2021 → Week 3 of Sept 2021), we noted the lowest median  $C_T$  range of all  
333 waves (27.0 - 27.5) (**FIG 3A**). The cumulative  $C_T$  data during each wave (**FIG 3C**) and  
334 extrapolated CoV2 genome copy concentrations (**FIG 3D**) are consistent with Wave 4 saliva  
335 samples having the highest virus concentrations of all waves. Wave 5 was the longest wave  
336 (Week 3 of Nov 2021 → Week 2 of Feb 2022) with daily PCR<sup>POS</sup> cases reaching a maximum  
337 of 523 on Jan 11, 2022. The  $C_T$  value range during Wave 5, which followed our community  
338 deadline for vaccine requirements, was significantly higher than that of Wave 4 (**FIG 3B**). The last  
339 wave before the COVID monitoring program ended, Wave 6 (Week 2 of Apr 2022 → Week 1 of  
340 May 2022), had lower  $C_T$  values than Wave 5 (**FIG 3B**). The lowest  $C_T$  value we ever observed  
341 was on Feb 18 2021 ( $C_T=14.2$ ).

342

#### 343 **IV. Each wave of CoV2 positivity corresponded to the emergence of a new CoV2 lineage** 344 **within our community.**

345

346 The CoV2 lineages present in each individual PCR<sup>POS</sup> sample during the same time periods as  
347 above are shown in **FIG 3B**, exceptions being samples with a  $C_T$  value of  $>33$  as these could not  
348 be sequenced due to the viral RNA levels being too low. Among sequenced samples, the median  
349 and mean ages of infected individuals were 21 and 23, respectively, and varied minimally during  
350 the monitoring period (supplemental **FIG S3**). Males were more likely to meet sequencing criteria  
351 (i.e. a  $C_T \leq 33$ ) than females during Waves 1-3 (supplemental **FIG S4**); this was not true of later  
352 Waves, however, and female representation was higher during the entire monitoring period

353 overall (supplemental **FIG S4**). During the period spanning Jan 2021 to mid-Feb 2021, the  
354 predominant lineage was B.1.2, which we hereafter refer to as CoV2<sup>US</sup> since it was among the  
355 first detected in our region of the United States (46-48). The period of CoV2<sup>US</sup> lineage  
356 predominance corresponds to Wave 1 in our community (**FIG 2, FIG 3B**). Beginning mid-Feb  
357 2021 and extending to mid-Mar 2021 was a period of time when an array of lineages which we  
358 collectively refer to as “non-VOC” were predominant, as they were more diverse compared to  
359 earlier and later testing periods and were never considered to be Variants of Concern (VOC).  
360 Although the CoV2<sup>US</sup> lineage was still being detected, Wave 2 primarily comprised of non-VOCs  
361 (**FIG 3B**). As the Ides of March approached in 2021, so too did two VOCs begin appearing with  
362 increasing frequency: the Alpha VOC (CoV2<sup>Alpha</sup>) and Gamma VOCs (CoV2<sup>Gamma</sup>). CoV2<sup>Alpha</sup> and  
363 CoV2<sup>Gamma</sup> were widely considered at that time to be more transmissible than previous lineages  
364 (9, 67). CoV2<sup>Alpha</sup> and CoV2<sup>Gamma</sup> were the primary lineages detected during Wave 3 (**FIG 3B**),  
365 and continued to predominate among the few positive samples collected during May 2021. The  
366 Beta VOC (CoV2<sup>Beta</sup>) only appeared once in our university community (Apr 15, 2021). Beginning  
367 Jun 2021 and continuing through Dec 2021 the new Delta VOC (CoV2<sup>Delta</sup>) made up the vast  
368 majority of PCR<sup>POS</sup> saliva samples (**FIG 3B**). CoV2<sup>Delta</sup> is more transmissible than CoV2<sup>Alpha</sup> and  
369 CoV2<sup>Gamma</sup> (68), and the period in which CoV2<sup>Delta</sup> predominated coincided with COVID Wave 4  
370 in our community (**FIG 2**). Wave 5, the penultimate and largest COVID wave, coincided with the  
371 emergence and dominance of the Omicron VOC (CoV2<sup>Omicron</sup>) subvariant, BA.1 (CoV2<sup>O-BA.1</sup>).  
372 Wave 6, final wave before our COVID monitoring program ended, was dominated by the  
373 CoV2<sup>Omicron</sup> subvariant BA.2 (CoV2<sup>O-BA.2</sup>) (**FIG 3B**). When considered alongside the C<sub>T</sub> values and  
374 CoV2 genome copy numbers that characterized each wave (**FIG 3C-D**), the above data  
375 demonstrate that the shift from CoV2<sup>US</sup> → CoV2<sup>Alpha</sup>/CoV2<sup>Gamma</sup> → CoV2<sup>Delta</sup> coincided with the  
376 virus becoming progressively more concentrated in the saliva of asymptomatic individuals, this  
377 trend ending after community vaccine requirements were established.

378

379 **V. Among pre-Omicron lineages, CoV2<sup>Delta</sup> elicited the highest levels of Spike-specific IgA**  
380 **and IgG in unvaccinated, asymptomatic individuals**

381  
382 In symptomatic CoV2 PCR<sup>POS</sup> individuals, CoV2-specific Ig levels in the circulation and airways  
383 increase at variable rates depending on the isotype (22). To assess whether CoV2-specific Ig was  
384 detectable in the saliva of asymptomatic CoV2 PCR<sup>POS</sup> individuals, as well as whether levels of  
385 the same Ig varied depending on the CoV2 lineage present, we used the same samples described  
386 above (i.e. those used for lineage identification) to measure saliva levels of CoV2 Spike-specific  
387 IgM (IgM<sup>Spike</sup>), CoV2 Spike-specific IgA (IgA<sup>Spike</sup>) and CoV2 Spike-specific IgG (IgG<sup>Spike</sup>) (**FIG 4**).  
388 Individuals vaccinated against COVID were excluded from this analysis (the vaccination record  
389 of each person in our university community was closely monitored during this time period), and  
390 saliva samples from individuals infected with CoV2<sup>Anc</sup>, CoV2<sup>Alpha</sup> and CoV2<sup>Gamma</sup> were collected  
391 prior to COVID vaccines being widely available in our community; therefore, no vaccine-elicited  
392 antibody responses would be expected in these samples. Among individuals infected with  
393 CoV2<sup>Delta</sup>, only unvaccinated individuals were included in the **FIG 4** analysis. To eliminate viral  
394 load as a confounding variable, only PCR<sup>POS</sup> saliva samples with similar C<sub>T</sub> range were used for  
395 Ig comparisons (C<sub>T</sub> range = 22-26). PCR<sup>NEG</sup> saliva collected in early 2020 from healthy individuals  
396 living in the US and no COVID history were used to estimate “pre-pandemic” levels of IgM<sup>Spike</sup>,  
397 IgA<sup>Spike</sup> of IgG<sup>Spike</sup> binding.

398  
399 Saliva IgM<sup>Spike</sup> (**FIG 4A**), IgA<sup>Spike</sup> (**FIG 4B**) and IgG<sup>Spike</sup> (**FIG 4C**) data are shown relative to which  
400 CoV2 lineage was detected in the same saliva donor (CoV2<sup>US</sup>, CoV2<sup>Alpha</sup>, CoV2<sup>Gamma</sup> or CoV2<sup>Delta</sup>)  
401 and are expressed as WHO binding antibody units, or BAUs. As shown in **FIG 4A-C**, respectively,  
402 nearly all PCR<sup>POS</sup> individuals had saliva IgM<sup>Spike</sup>, IgA<sup>Spike</sup> and IgG<sup>Spike</sup> levels that were above “pre-  
403 pandemic” levels, regardless of whether they were infected with CoV2<sup>US</sup>, CoV2<sup>Alpha</sup>, CoV2<sup>Gamma</sup>  
404 or CoV2<sup>Delta</sup>. There were, however, three noteworthy differences between PCR<sup>POS</sup> individuals

405 depending on the lineage present. First, whereas individuals infected with CoV2<sup>US</sup> and CoV2<sup>Alpha</sup>  
406 had similar IgM<sup>Spike</sup> levels, those infected with CoV2<sup>Gamma</sup> and CoV2<sup>Delta</sup> had higher IgM<sup>Spike</sup> levels  
407 relative to those infected with CoV2<sup>US</sup> (**FIG 4A**). Second, saliva IgA<sup>Spike</sup> levels were similar  
408 between individuals infected with CoV2<sup>US</sup>, CoV2<sup>Alpha</sup> and CoV2<sup>Gamma</sup>; CoV2<sup>Delta</sup> infected  
409 individuals, on the other hand, had significantly higher IgA<sup>Spike</sup> levels compared to those infected  
410 with CoV2<sup>US</sup>, CoV2<sup>Alpha</sup> or CoV2<sup>Gamma</sup> (**FIG 4B**). Third, saliva IgG<sup>Spike</sup> levels were elevated in  
411 CoV2<sup>Alpha</sup>-infected individuals relative to CoV2<sup>US</sup>-infected individuals (**FIG 4C**); however and  
412 analogous to IgA<sup>Spike</sup> differences (**FIG 4B**), CoV2<sup>Delta</sup>-infected individuals had significantly higher  
413 IgG<sup>Spike</sup> levels compared to those infected with CoV2<sup>US</sup>, CoV2<sup>Alpha</sup> or CoV2<sup>Gamma</sup> (**FIG 4C**). For  
414 IgM<sup>Spike</sup>, IgA<sup>Spike</sup> and IgG<sup>Spike</sup> measurements, the recombinant Spike antigen used for Ig detection  
415 was identical to that of CoV2<sup>Anc</sup>, as this enabled data transformation to WHO BAU (see *Methods*);  
416 the same patterns were observed, however, when the same saliva samples were tested against  
417 recombinant CoV2<sup>Alpha</sup>, CoV2<sup>Beta</sup>, and CoV2<sup>Gamma</sup> Spike antigens (**Supplemental FIG S5**).

418

## 419 **VI. Following infection of unvaccinated individuals, IgG<sup>Spike</sup> and IgG<sup>RBD</sup> persisted at higher** 420 **levels in saliva than IgG<sup>N</sup>**

421

422 To determine the extent to which CoV2-specific IgG in saliva was sustained over time, we  
423 performed the analysis shown in **FIG 5** wherein saliva IgG<sup>Spike</sup> levels, as well as Nucleocapsid  
424 (N)-specific IgG (IgG<sup>N</sup>) levels, were compared across two groups of individuals: “New<sup>POS</sup>”  
425 individuals who, at the time of saliva collection, were positive for either CoV2<sup>US</sup> or CoV2<sup>Alpha</sup>;  
426 “Prior<sup>POS</sup>” individuals who were uninfected at the time of saliva collection, but had been PCR<sup>POS</sup>  
427 3-9 months earlier. In this instance, saliva samples from Prior<sup>POS</sup> individuals were collected in May  
428 2021. Most individuals in our Prior<sup>POS</sup> cohort were infected during the Autumn 2020 semester,  
429 before COVID vaccines were available; therefore, any saliva IgG<sup>Spike</sup> or IgG<sup>N</sup> present would have



430 formed after natural infection (not vaccination). As in the previous figure, individuals with a record  
431 of COVID vaccination were excluded from this analysis.

432  
433 Among New<sup>POS</sup> individuals, saliva IgG<sup>N</sup> levels were similar regardless of whether they were  
434 infected with CoV2<sup>US</sup> or CoV2<sup>Alpha</sup> (**FIG 5A**), as were saliva IgG<sup>Spike</sup> levels (**FIG 5B**; note the data  
435 points in the first two columns of **FIG 5B** are the same as those in the first two columns of **FIG**  
436 **4C**). Relative to New<sup>POS</sup> individuals, saliva IgG<sup>N</sup> levels in Prior<sup>POS</sup> individuals were higher (**FIG**  
437 **5A**); however, the difference in saliva IgG<sup>Spike</sup> levels between New<sup>POS</sup> versus Prior<sup>POS</sup> individuals  
438 was more pronounced (**FIG 5B**). Saliva IgG<sup>Spike</sup> levels were highest in Prior<sup>POS</sup> individuals (**FIG**  
439 **5B**) and reacted against the Spike RBD domain (**FIG 5C**). These results indicate that although  
440 IgG<sup>N</sup> and IgG<sup>Spike</sup> both persist in saliva following natural infection, IgG<sup>Spike</sup> persists at higher levels  
441 and reacts against Spike regions that are essential for ACE2 binding (i.e., the RBD).

442  
443 **VII. Individuals with breakthrough CoV<sup>Delta</sup> infections had comparable saliva IgG<sup>Spike</sup> levels**  
444 **to those of uninfected, vaccinated individuals.**

445  
446 During the period of Dec 2020 – Mar 2021, COVID vaccination was prioritized and available to  
447 the elderly and other individuals at increased risk of severe disease (e.g. healthcare workers, first  
448 responders). In Ohio, beginning on Mar 22 2021, individuals who were 16 years or older could  
449 receive a COVID vaccine, including all college students (69). Despite the widespread availability  
450 of vaccines by our Autumn 2021 semester, CoV2<sup>Delta</sup> lineage infections occurred among  
451 unvaccinated (Vax<sup>NEG</sup>) individuals and vaccinated (Vax<sup>POS</sup>) individuals. The term “breakthrough  
452 infection” is older than COVID (70) but is now commonly applied to individuals who are PCR<sup>POS</sup>  
453 despite their being Vax<sup>POS</sup>. Since BNT162b2, mRNA-1273 and Ad26.COV2.S were each  
454 designed to elicit an Ig response against CoV2 Spike (since it is essential for CoV2 infection of  
455 ACE2-expressing cells), we assessed whether breakthrough infections with CoV2<sup>Delta</sup> were



456 associated with lower levels of Spike-specific Ig in saliva compared to PCR (neg) vaccinates.  
457 Shown in **FIG 6** are saliva levels of IgM<sup>Spike</sup>, IgA<sup>Spike</sup> and IgG<sup>Spike</sup> in three groups of individuals:  
458 VAX<sup>NEG</sup>PCR<sup>POS</sup> individuals infected with CoV2<sup>Delta</sup>, VAX<sup>POS</sup>PCR<sup>POS</sup> individuals infected with  
459 CoV2<sup>Delta</sup>, and VAX<sup>POS</sup>PCR<sup>NEG</sup> individuals. Saliva from VAX<sup>NEG</sup>PCR<sup>POS</sup> and VAX<sup>POS</sup>PCR<sup>POS</sup>  
460 individuals was collected during Wave 4 (**FIG 2**), when community viral burdens were their highest  
461 (**FIG 3D**); saliva from VAX<sup>POS</sup>PCR<sup>NEG</sup> individuals was collected shortly after Wave 4 had passed.  
462 These results demonstrate that VAX<sup>POS</sup>PCR<sup>POS</sup> and VAX<sup>POS</sup>PCR<sup>NEG</sup> groups each had significantly  
463 higher saliva IgG<sup>Spike</sup> levels than VAX<sup>NEG</sup>PCR<sup>POS</sup> individuals (**FIG 6C**). Furthermore, the saliva  
464 IgG<sup>Spike</sup> levels of VAX<sup>POS</sup>PCR<sup>POS</sup> and VAX<sup>POS</sup>PCR<sup>NEG</sup> groups did not significantly differ from one  
465 another (**FIG 6C**). Notably, although saliva IgM<sup>Spike</sup> levels were indistinguishable across groups  
466 (**FIG 6A**), VAX<sup>NEG</sup>PCR<sup>POS</sup> individuals were distinguished by the highest levels of saliva IgA<sup>Spike</sup>  
467 (**FIG 6B**). Similar trends were observed using recombinant CoV2<sup>Alpha</sup>, CoV2<sup>Beta</sup>, CoV2<sup>Gamma</sup> and  
468 CoV2<sup>Delta</sup> Spike as capture antigens (**Supplemental FIG S6**). We conclude from this that COVID  
469 vaccination increased saliva IgG<sup>Spike</sup> levels in our university community as intended, the saliva  
470 IgG<sup>Spike</sup> levels in all vaccinees being comparable (regardless of whether they had a breakthrough  
471 CoV<sup>Delta</sup> infection) and significantly higher than the saliva IgG<sup>Spike</sup> levels of unvaccinated, infected  
472 individuals.

473

474 **VIII. Despite comparable Spike-specific Ig levels, CoV2<sup>Delta</sup>-infected vaccinee saliva was**  
475 **less capable of Spike:ACE2 inhibition, relative to uninfected vaccinees.**

476

477 Since the presence of CoV2-specific Ig does not equate to its having neutralization capacity (71),  
478 we next compared the ability of Vax<sup>NEG</sup>PCR<sup>POS</sup>, Vax<sup>POS</sup>PCR<sup>POS</sup> and Vax<sup>POS</sup>PCR<sup>NEG</sup> saliva  
479 samples to inhibit Spike:ACE2 interactions. We quantified inhibitory activity using an ACE2  
480 displacement assay (**FIG 7A**), wherein plate-bound Spike was incubated with the same saliva  
481 samples above (i.e., those of **FIG 6**), followed by washing and addition of a luminescent probe-

482 conjugated, recombinant form of human ACE2. The extent to which luminescence declined  
483 relative to non-saliva treated wells was used to derive a percent inhibition value for each individual  
484 sample (see *Methods* for additional details). The results of this analysis are shown in **FIG 7B** and  
485 demonstrate that there were differences between cohorts, the inhibitory activity of Vax<sup>POS</sup>PCR<sup>NEG</sup>  
486 saliva being significantly higher than that of Vax<sup>NEG</sup>PCR<sup>POS</sup> saliva (**FIG 7B**). The inhibitory activity  
487 of Vax<sup>POS</sup>PCR<sup>POS</sup> saliva (median=12) was 50% higher than that of Vax<sup>NEG</sup>PCR<sup>POS</sup> saliva  
488 (median=8), but 25% lower than that of Vax<sup>POS</sup>PCR<sup>NEG</sup> saliva (median=16); as a whole, however,  
489 the inhibitory activity of Vax<sup>POS</sup>PCR<sup>POS</sup> saliva did not significantly differ from that of Vax<sup>NEG</sup>PCR<sup>POS</sup>  
490 saliva, nor did it significantly differ from Vax<sup>POS</sup>PCR<sup>NEG</sup> saliva (**FIG 7B**). Within the Vax<sup>NEG</sup>PCR<sup>POS</sup>  
491 cohort, there were no significant correlations between these samples' inhibitory activity and their  
492 IgM<sup>Spike</sup> (**FIG 7C**), IgA<sup>Spike</sup> (**FIG 7D**) or IgG<sup>Spike</sup> concentrations (**FIG 7E**). This was also true of the  
493 Vax<sup>POS</sup>PCR<sup>POS</sup> cohort, as no significant correlations were observed between these samples'  
494 inhibitory activity and their IgM<sup>Spike</sup> (**FIG 7F**), IgA<sup>Spike</sup> (**FIG 7G**) or IgG<sup>Spike</sup> concentrations (**FIG 7H**).  
495 Within the Vax<sup>POS</sup>PCR<sup>NEG</sup> cohort, there were significant correlations between samples' inhibitory  
496 activity and their IgA<sup>Spike</sup> concentration (**FIG 7J**), as well as their IgG<sup>Spike</sup> concentration (**FIG 7K**),  
497 but not their IgM<sup>Spike</sup> concentration (**FIG 7I**). When considered alongside the data shown in **FIG**  
498 **6**, we conclude COVID vaccination led to increases in saliva IgG<sup>Spike</sup> concentrations, the levels  
499 being similar between vaccinees who had a breakthrough CoV2<sup>Delta</sup> infection (Vax<sup>POS</sup>PCR<sup>POS</sup>) and  
500 vaccinees who did not (Vax<sup>POS</sup>PCR<sup>NEG</sup>), but that during Wave 4 the antibodies in Vax<sup>POS</sup>PCR<sup>POS</sup>  
501 saliva were limited in their ability to inhibit Spike, the inhibition values being intermediate between  
502 Vax<sup>POS</sup>PCR<sup>NEG</sup> saliva (which had the highest inhibition values) and Vax<sup>NEG</sup>PCR<sup>POS</sup> controls (which  
503 had the lowest inhibition values).

504 **DISCUSSION**

505

506 The spread of CoV2 to the US marked the beginning of an extraordinary period wherein a novel  
507 respiratory virus transmitted and evolved in a population with no prior immunity, our primary  
508 defenses being behavioral changes (e.g., masking and physical distancing) until the advent of  
509 effective vaccines. The first COVID case in the US occurred in January 2020 (72). It was soon  
510 discovered that CoV2 caused both symptomatic and asymptomatic infections (the latter being  
511 more common in young adults), that asymptomatic individuals could transmit CoV2 (73, 74), and  
512 that isolation of symptomatic individuals alone would not sufficiently “flatten the curve” of COVID  
513 incidence (37, 75). By April 2020, most US universities shut down on-campus activities so as to  
514 limit CoV2 transmission among their students, staff, and faculty. Many universities established  
515 COVID monitoring programs prior to campus reopening as a means of identifying symptomatic  
516 and asymptomatic individuals. These monitoring programs varied in their testing modalities (PCR-  
517 or antigen-based), cadence (weekly versus biweekly testing) and sample pooling practices  
518 (pooled versus individual testing); all monitoring programs, however, had the same goal in mind:  
519 enabling safe resumption of on-campus classes and activities. Now that mass COVID testing  
520 programs have ended in US, enabling time for processing and reflection, we are sharing the  
521 results of our monitoring program which we believe are most relevant to the ongoing issues of  
522 community spread, the longevity of mucosal Ig following natural infection, breakthrough infections,  
523 and the utility of saliva for assessing Ig responses to newer Omicron subvariants and booster  
524 vaccines.

525

526 That the COVID waves in our campus community mirrored those which occurred in surrounding  
527 counties, instead of preceding the surrounding county waves, touches on an important question  
528 at the time regarding campus reopening: what if any contribution would the influx of students have  
529 on COVID incidence in surrounding communities. In January 2021, student returns to university

530 campuses were a contentious subject in the US due to the potential risk of contracting the virus  
531 and subsequent transmission to surrounding communities. COVID vaccines were not yet widely  
532 available to young adults, and—fairly or unfairly—university students were perceived as being  
533 more cavalier in their adherence to masking protocols and social distancing. Whether or not the  
534 reopening of a given college or university contributed to higher off-campus COVID transmission  
535 will depend on several variables (e.g. whether a school was in a state that mandated mask-  
536 wearing) (76), but in our case the COVID wave that occurred in our university in January 2021  
537 (Wave 1) peaked during the tail end of one which had been ongoing in surrounding counties  
538 (compare **FIG 2** to supplemental **FIG S2**). This was also true in Aug 2022, when our campus  
539 reopened after summer break and experienced Wave 4, which followed the Delta wave that had  
540 already begun in surrounding counties. The timing of Wave 1 and Wave 4 in relation to those in  
541 surrounding counties is inconsistent with the argument that our university reopening contributed  
542 to COVID incidence in the surrounding communities. Studies at other large universities with  
543 COVID policies and monitoring programs similar to our own support this conclusion (77-79).

544

545 Early in the COVID pandemic, it was unknown whether natural infection would give rise to Ig  
546 responses that were durable and protective, as those against common seasonal coronaviruses  
547 are short-lived (only 6 months in some cases) (80), or worse still whether the Ig response would  
548 actually enhance infection or disease (81-84). Regarding the durability and protective capacity of  
549 the antibody response to natural CoV2 infection, current knowledge on this subject was recently  
550 reviewed (71). In our study, at the time of initial PCR positivity we could already detect elevations  
551 in CoV2-specific Ig (IgM, IgA, and to a lesser extent IgG) in the saliva of asymptomatic individuals,  
552 the degree to which varied by lineage, CoV2<sup>Delta</sup> being the most immunogenic of the lineages we  
553 assessed. Saliva levels of CoV2-specific IgG were substantially higher in Prior<sup>POS</sup> individuals  
554 compared to New<sup>POS</sup> individuals, were directed against Spike, Spike RBD and (to a lesser extent)

555 the N protein. Potential reasons why Spike-specific IgG ( $\text{IgG}^{\text{Spike}}$ ) levels were higher than those  
556 of N-specific IgG ( $\text{IgG}^{\text{N}}$ ) include Spike being more antigenic, or alternatively it may reflect an  
557 inherent inability of  $\text{IgG}^{\text{N}}$  to persist in saliva relative to  $\text{IgG}^{\text{Spike}}$ , as is the case in plasma (85). With  
558 regards to antibody dependent enhancement (ADE) of virus infection or subsequent disease, this  
559 has primarily been studied in the context of flaviviruses (86) and is the phenomenon wherein non-  
560 neutralizing antibodies amplify viral entry (instead of blocking it). ADE occurs in cell culture and  
561 animal infection models of SARS-CoV-1 (87, 88) and MERS-CoV (89), as well as feline infectious  
562 peritonitis coronavirus (FIPV) (90, 91). B cells from convalescent COVID patients can produce  
563 monoclonal antibodies that enhance the ACE2-binding capacity of Spike and CoV2 infectivity in  
564 cell culture (92, 93); however, these same monoclonal antibodies did not enhance CoV2 infection  
565 in mouse or macaque models (92), nor has evidence of vaccine-enhanced disease (VED) been  
566 observed in the hamster, ferret or macaque COVID models (94, 95). The circumstances and  
567 extent to which ADE occurring following CoV2 infection nevertheless remains an active area of  
568 research (96-98).

569 When COVID vaccine doses were in short supply (early 2021), university students were generally  
570 not considered a vaccine priority by national public health agencies. By the time COVID vaccines  
571 were widely available, non-trivial levels of vaccine hesitancy had arisen among university students  
572 in many countries for many reasons (99). Vaccine hesitancy was reinforced by the occurrence of  
573 breakthrough infections with CoV2<sup>Delta</sup> (100, 101), the first lineage to emerge after vaccines had  
574 become more widely available in Summer 2021. If vaccines were effective, conventional logic at  
575 the time being, how then could a vaccinated individual still become PCR<sup>POS</sup>? Our current  
576 understanding is that a combination of three factors affects susceptibility to breakthrough  
577 infections: (1) antibody levels at the time of virus exposure, (2) the neutralizing capacity of these  
578 antibodies, and (3) the amount of virus to which a vaccinee is exposed. Our data demonstrate  
579 that saliva  $\text{IgG}^{\text{Spike}}$  levels were comparable between CoV<sup>Delta</sup>-infected vaccinees ( $\text{Vax}^{\text{POS}}\text{PCR}^{\text{POS}}$ )

580 and uninfected vaccinees ( $Vax^{POS}PCR^{NEG}$ ), but that the collective inhibitory capacity of this  
581  $IgG^{Spike}$  and other saliva antibodies differed between groups, with  $Vax^{POS}PCR^{POS}$  saliva being less  
582 inhibitory than  $Vax^{POS}PCR^{NEG}$  saliva (**FIG 7B**). If the saliva Ig response is representative of that  
583 which occurs in other parts of the upper airway, then the combination of weak neutralization  
584 capacity and higher viral loads, which were typical of the Delta wave (Wave 4 of **FIG 3D**), created  
585 conditions that were conducive to  $CoV2^{Delta}$  breakthrough infections. Our observation that  
586  $CoV2^{Delta}$  was more concentrated in saliva of asymptomatic individuals is consistent with work  
587 showing  $CoV2^{Delta}$ -infected individuals were more likely to transmit virus before developing  
588 symptoms, compared to individuals infected with pre-Delta lineages (102).

589  
590 The largest COVID wave our university community experienced was caused by the Omicron  
591 lineage. The Omicron lineage spread rapidly after its first detection in southern Africa in November  
592 2021 (11, 103); the >30 amino acid substitutions in Spike enabled Omicron to bind ACE2 with  
593 higher affinity, as well as escape the anti-Spike antibody response elicited by either natural  
594 infection or vaccination with pre-Omicron lineages or vaccines (104-106). The immunoevasive  
595 properties of Omicron are consistent with its causing a COVID wave in our community after  
596 vaccine mandates had been established. The rapidity with which Omicron took over was observed  
597 in other university settings which, like ours, were highly vaccinated at the time (107). Compared  
598 to infections caused by the Delta lineage, those by Omicron tend to cause less severe disease  
599 (108), which may be due in whole or part to its being enriched in upper airways (including the oral  
600 cavity) as opposed to the lower airways (39-43). Omicron variants BA.1 and BA.2 were the last  
601 lineages detected in our university community before our testing program ended in May 2022.  
602 Since then  $CoV2$  has continued to evolve, there now being additional Omicron variants (BA.4,  
603 BA.5, BA.2.12.1, BA.2.75, XBB) and “Scrabble” subvariants (BQ.1 and BQ1.1) with Spike protein  
604 sequences that further desensitize the virus to *in vitro* neutralization by many (but not all)  
605 monoclonal therapies (109-112), as well as convalescent plasma (113). Since Omicron has a

606 higher tropism for the nasopharyngeal and oral cavities than that of pre-Omicron lineages (39-  
607 43), saliva antibodies may be more important inhibitors of Omicron transmission than plasma or  
608 lower airway antibodies, and saliva—the collection of which is far easier than blood—may be  
609 more suitable for rapid determination of whether someone has neutralizing capacity against future  
610 CoV2 variants that have yet to emerge.

611  
612 The limitations of our study are as follows: (1) Since participants in our monitoring program  
613 provided saliva on a weekly basis, we cannot know the exact date on which someone was  
614 infected, rather only that they were infected 0-7 days prior to their scheduled test; (2) By only  
615 measuring CoV2-specific Ig in individuals whose  $C_T$  values fell within a narrow range (thus  
616 normalizing for viral load), we cannot make any statements regarding the relationship between  
617 lower or higher  $C_T$  values and CoV2-specific Ig levels; (3) Although we can correlate saliva  
618 samples' Spike inhibition capacity with their corresponding  $IgM^{Spike}$ ,  $IgA^{Spike}$  and  $IgG^{Spike}$  levels, we  
619 cannot definitively state which of these isotypes most contributed to inhibition; (4) Finally, we did  
620 not measure CoV2-specific Ig levels in individuals infected with CoV2<sup>O-BA.1</sup> or CoV2<sup>O-BA.2</sup>, a reason  
621 being at that stage in the pandemic (i.e. Waves 5-6 in our community) vaccine mandates were in  
622 place, and boosters were becoming available, making it difficult if not impossible to discern what  
623 levels of  $IgM^{Spike}$ ,  $IgA^{Spike}$  and  $IgG^{Spike}$  were due to vaccination versus boosters versus Omicron  
624 infection.

625 **ACKNOWLEDGEMENTS**

626 We would like to acknowledge the hundreds of Ohio State staff and student employees who  
627 collected, transported and processed saliva during the period that our campus testing program  
628 was active. We would also like to acknowledge the research compliance expertise of Tish  
629 Denlinger (Office of Responsible Research Practices) and Angela Emerson (Office of Research),  
630 the technical expertise of Dr. Arpita Agrawal, Brian Gribble, and Trina Wemlinger (Center for  
631 Clinical and Translational Science), the general lab assistance of Sam Hagenbaugh and Elizabeth  
632 Griffin (TOPS Program), and documentation assistance of Marie Klever (Infectious Disease  
633 Institute). This work was supported by the Analytical and Development Laboratory of the Clinical  
634 Research Center/Center for Clinical Research Management of Wexner Medical Center, the OSU  
635 College of Medicine (Microbial Infection & Immunity Department), OSU College of Public Health  
636 (Epidemiology Division), and the OSU Infectious Disease Institute.



## 637 REFERENCES

- 638 1. G. T. Keusch *et al.*, Pandemic origins and a One Health approach to preparedness and  
639 prevention: Solutions based on SARS-CoV-2 and other RNA viruses. *Proc Natl Acad Sci U*  
640 *S A* **119**, e22028711119 (2022).
- 641 2. <https://covid19.who.int>.
- 642 3. S. E. Galloway *et al.*, Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December  
643 29, 2020-January 12, 2021. *MMWR Morb Mortal Wkly Rep* **70**, 95-99 (2021).
- 644 4. H. Tegally *et al.*, Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* **592**,  
645 438-443 (2021).
- 646 5. J. P. Evans, S. L. Liu, Role of host factors in SARS-CoV-2 entry. *J Biol Chem* **297**, 100847  
647 (2021).
- 648 6. D. Zhou *et al.*, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-  
649 induced sera. *Cell* **184**, 2348-2361 e2346 (2021).
- 650 7. E. Volz *et al.*, Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*  
651 **593**, 266-269 (2021).
- 652 8. N. G. Davies *et al.*, Increased mortality in community-tested cases of SARS-CoV-2 lineage  
653 B.1.1.7. *Nature* **593**, 270-274 (2021).
- 654 9. N. R. Faria *et al.*, Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus,  
655 Brazil. *Science* **372**, 815-821 (2021).
- 656 10. P. Mlcochova *et al.*, SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.  
657 *Nature* **599**, 114-119 (2021).
- 658 11. R. Viana *et al.*, Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern  
659 Africa. *Nature* **603**, 679-686 (2022).
- 660 12. J. Scholey *et al.*, Life expectancy changes since COVID-19. *Nat Hum Behav*, (2022).
- 661 13. J. Q. Xu, S. L. Murphy, K. D. Kochanek, E. Arias, Mortality in the United States, 2021. *NCHS*  
662 *Data Brief*, no 456. Hyattsville, MD: National Center for Health Statistics. , (2022).
- 663 14. J. Zhao *et al.*, Rapid generation of a mouse model for Middle East respiratory syndrome.  
664 *Proc Natl Acad Sci U S A* **111**, 4970-4975 (2014).
- 665 15. Y. Yao *et al.*, An animal model of MERS produced by infection of rhesus macaques with  
666 MERS coronavirus. *J Infect Dis* **209**, 236-242 (2014).
- 667 16. T. H. Jang *et al.*, The structure of a novel antibody against the spike protein inhibits Middle  
668 East respiratory syndrome coronavirus infections. *Sci Rep* **12**, 1260 (2022).
- 669 17. L. Du *et al.*, A conformation-dependent neutralizing monoclonal antibody specifically  
670 targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike  
671 protein. *J Virol* **88**, 7045-7053 (2014).
- 672 18. C. Ma *et al.*, Intranasal vaccination with recombinant receptor-binding domain of MERS-  
673 CoV spike protein induces much stronger local mucosal immune responses than  
674 subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.  
675 *Vaccine* **32**, 2100-2108 (2014).
- 676 19. F. Song *et al.*, Middle East respiratory syndrome coronavirus spike protein delivered by  
677 modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. *J Virol* **87**,  
678 11950-11954 (2013).

- 679 20. L. Du *et al.*, Identification of a receptor-binding domain in the S protein of the novel  
680 human coronavirus Middle East respiratory syndrome coronavirus as an essential target  
681 for vaccine development. *J Virol* **87**, 9939-9942 (2013).
- 682 21. H. Mou *et al.*, The receptor binding domain of the new Middle East respiratory syndrome  
683 coronavirus maps to a 231-residue region in the spike protein that efficiently elicits  
684 neutralizing antibodies. *J Virol* **87**, 9379-9383 (2013).
- 685 22. D. Sterlin *et al.*, IgA dominates the early neutralizing antibody response to SARS-CoV-2.  
686 *Sci Transl Med* **13**, (2021).
- 687 23. D. Kline *et al.*, Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel  
688 poststratification approach with multiple diagnostic tests. *Proc Natl Acad Sci U S A* **118**,  
689 (2021).
- 690 24. D. F. Robbiani *et al.*, Convergent antibody responses to SARS-CoV-2 in convalescent  
691 individuals. *Nature* **584**, 437-442 (2020).
- 692 25. E. M. Bloch *et al.*, Deployment of convalescent plasma for the prevention and treatment  
693 of COVID-19. *J Clin Invest* **130**, 2757-2765 (2020).
- 694 26. L. Estcourt, J. Callum, Convalescent Plasma for Covid-19 - Making Sense of the  
695 Inconsistencies. *N Engl J Med* **386**, 1753-1754 (2022).
- 696 27. [https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-  
697 against-covid-19-issuing-emergency-use-authorization-first-covid-19](https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19).
- 698 28. [https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-  
699 fight-against-covid-19-issuing-emergency-use-authorization-second-covid](https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid).
- 700 29. [https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-  
701 authorization-third-covid-19-vaccine](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine).
- 702 30. D. H. Barouch, Covid-19 Vaccines - Immunity, Variants, Boosters. *N Engl J Med* **387**, 1011-  
703 1020 (2022).
- 704 31. A. G. Johnson *et al.*, COVID-19 Incidence and Death Rates Among Unvaccinated and Fully  
705 Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron  
706 Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021. *MMWR Morb  
707 Mortal Wkly Rep* **71**, 132-138 (2022).
- 708 32. L. R. Baden *et al.*, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*  
709 **384**, 403-416 (2021).
- 710 33. F. P. Polack *et al.*, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J  
711 Med* **383**, 2603-2615 (2020).
- 712 34. D. Bojadzic *et al.*, Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-  
713 Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. *ACS Infect  
714 Dis* **7**, 1519-1534 (2021).
- 715 35. Y. Huang, C. Yang, X. F. Xu, W. Xu, S. W. Liu, Structural and functional properties of SARS-  
716 CoV-2 spike protein: potential antiviral drug development for COVID-19. *Acta Pharmacol  
717 Sin* **41**, 1141-1149 (2020).
- 718 36. W. S. Hart, P. K. Maini, R. N. Thompson, High infectiousness immediately before COVID-  
719 19 symptom onset highlights the importance of continued contact tracing. *Elife* **10**,  
720 (2021).
- 721 37. M. A. Johansson *et al.*, SARS-CoV-2 Transmission From People Without COVID-19  
722 Symptoms. *JAMA Netw Open* **4**, e2035057 (2021).

- 723 38. N. Huang *et al.*, SARS-CoV-2 infection of the oral cavity and saliva. *Nat Med* **27**, 892-903  
724 (2021).
- 725 39. M. Miguères *et al.*, Omicron Wave SARS-CoV-2 Diagnosis: Evaluation of Saliva, Anterior  
726 Nasal, and Nasopharyngeal Swab Samples. *Microbiol Spectr*, e0252122 (2022).
- 727 40. G. Marais *et al.*, Improved oral detection is a characteristic of Omicron infection and has  
728 implications for clinical sampling and tissue tropism. *J Clin Virol* **152**, 105170 (2022).
- 729 41. R. Suzuki *et al.*, Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron  
730 variant. *Nature* **603**, 700-705 (2022).
- 731 42. K. P. Y. Hui *et al.*, Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of  
732 the human upper and lower respiratory tract. *EBioMedicine* **83**, 104232 (2022).
- 733 43. B. Meng *et al.*, Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and  
734 fusogenicity. *Nature* **603**, 706-714 (2022).
- 735 44. <https://www.fda.gov/media/141192/download>.
- 736 45. C. B. F. Vogels *et al.*, SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-  
737 2 testing capacity. *Med (N Y)* **2**, 263-280 e266 (2021).
- 738 46. V. L. Hale *et al.*, SARS-CoV-2 infection in free-ranging white-tailed deer. *Nature* **602**, 481-  
739 486 (2022).
- 740 47. A. Rambaut *et al.*, A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist  
741 genomic epidemiology. *Nat Microbiol* **5**, 1403-1407 (2020).
- 742 48. E. B. Hodcroft *et al.*, Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike  
743 protein variants affecting amino acid position 677. *medRxiv*, (2021).
- 744 49. E. I. Patterson *et al.*, Methods of Inactivation of SARS-CoV-2 for Downstream Biological  
745 Assays. *J Infect Dis* **222**, 1462-1467 (2020).
- 746 50. [https://www.dispatch.com/story/news/2020/03/09/3-ohioans-test-positive-](https://www.dispatch.com/story/news/2020/03/09/3-ohioans-test-positive-for/1553817007/)  
747 [for/1553817007/](https://www.dispatch.com/story/news/2020/03/09/3-ohioans-test-positive-for/1553817007/).
- 748 51. [https://www.thelantern.com/2020/03/ohio-state-suspends-classes-until-march-30-due-](https://www.thelantern.com/2020/03/ohio-state-suspends-classes-until-march-30-due-to-coronavirus-outbreak/)  
749 [to-coronavirus-outbreak/](https://www.thelantern.com/2020/03/ohio-state-suspends-classes-until-march-30-due-to-coronavirus-outbreak/).
- 750 52. [https://www.thelantern.com/2020/07/ohio-state-announces-proactive-covid-19-](https://www.thelantern.com/2020/07/ohio-state-announces-proactive-covid-19-testing-measures-no-specific-guidance-on-when-to-close-campus/)  
751 [testing-measures-no-specific-guidance-on-when-to-close-campus/](https://www.thelantern.com/2020/07/ohio-state-announces-proactive-covid-19-testing-measures-no-specific-guidance-on-when-to-close-campus/).
- 752 53. <https://news.osu.edu/ohio-state-announces-vaccination-requirement/>.
- 753 54. Data were obtained from <https://coronavirus.ohio.gov/dashboards/overview> accessed  
754 11.14.22.
- 755 55. Ohio Department of Health COVID-19 Dashboard.  
756 <https://coronavirus.ohio.gov/dashboards>.
- 757 56. [https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-](https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic)  
758 [international-health-regulations-\(2005\)-emergency-committee-regarding-the-](https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic)  
759 [coronavirus-disease-\(covid-19\)-pandemic](https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic).
- 760 57. [https://www.daytondailynews.com/local/delta-variant-in-ohio-what-you-should-](https://www.daytondailynews.com/local/delta-variant-in-ohio-what-you-should-know/WQ3EI57ZPNA67OC346RKSDCKAU/)  
761 [know/WQ3EI57ZPNA67OC346RKSDCKAU/](https://www.daytondailynews.com/local/delta-variant-in-ohio-what-you-should-know/WQ3EI57ZPNA67OC346RKSDCKAU/).
- 762 58. [https://governor.ohio.gov/media/news-and-media/COVID-19-Update-Vaccinations-](https://governor.ohio.gov/media/news-and-media/COVID-19-Update-Vaccinations-Increasing-Delta-Variant-Local-Efforts-Encouraged-08062021)  
763 [Increasing-Delta-Variant-Local-Efforts-Encouraged-08062021](https://governor.ohio.gov/media/news-and-media/COVID-19-Update-Vaccinations-Increasing-Delta-Variant-Local-Efforts-Encouraged-08062021).
- 764 59. [https://www.10tv.com/article/news/health/coronavirus/covid-variant-dashboard/530-](https://www.10tv.com/article/news/health/coronavirus/covid-variant-dashboard/530-0a10581c-cf0b-4255-b2f0-46984b0cbd30)  
765 [0a10581c-cf0b-4255-b2f0-46984b0cbd30](https://www.10tv.com/article/news/health/coronavirus/covid-variant-dashboard/530-0a10581c-cf0b-4255-b2f0-46984b0cbd30).
- 766 60. <https://odh.ohio.gov/media-center/odh-news-releases/odh-news-release-12-11-21>.

- 767 61. [https://www.thelantern.com/2021/12/first-cases-of-omicron-covid-19-variant-](https://www.thelantern.com/2021/12/first-cases-of-omicron-covid-19-variant-detected-in-ohio/)  
768 [detected-in-ohio/](https://www.thelantern.com/2021/12/first-cases-of-omicron-covid-19-variant-detected-in-ohio/).
- 769 62. Y. Woodbridge, S. Amit, A. Huppert, N. M. Kopelman, Viral load dynamics of SARS-CoV-2  
770 Delta and Omicron variants following multiple vaccine doses and previous infection. *Nat*  
771 *Commun* **13**, 6706 (2022).
- 772 63. M. Trunfio *et al.*, Determinants of SARS-CoV-2 Contagiousness in Household Contacts of  
773 Symptomatic Adult Index Cases. *Front Microbiol* **13**, 829393 (2022).
- 774 64. M. Levine-Tiefenbrun *et al.*, Viral loads of Delta-variant SARS-CoV-2 breakthrough  
775 infections after vaccination and booster with BNT162b2. *Nat Med* **27**, 2108-2110 (2021).
- 776 65. S. Al Bayat *et al.*, Can the cycle threshold (Ct) value of RT-PCR test for SARS CoV2 predict  
777 infectivity among close contacts? *J Infect Public Health* **14**, 1201-1205 (2021).
- 778 66. H. Kawasuji *et al.*, Transmissibility of COVID-19 depends on the viral load around onset in  
779 adult and symptomatic patients. *PLoS One* **15**, e0243597 (2020).
- 780 67. N. G. Davies *et al.*, Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in  
781 England. *Science* **372**, (2021).
- 782 68. W. S. Hart *et al.*, Generation time of the alpha and delta SARS-CoV-2 variants: an  
783 epidemiological analysis. *Lancet Infect Dis* **22**, 603-610 (2022).
- 784 69. [https://www.thelantern.com/2021/04/dewine-all-ohio-college-students-will-have-](https://www.thelantern.com/2021/04/dewine-all-ohio-college-students-will-have-access-to-single-dose-covid-vaccine/)  
785 [access-to-single-dose-covid-vaccine/](https://www.thelantern.com/2021/04/dewine-all-ohio-college-students-will-have-access-to-single-dose-covid-vaccine/).
- 786 70. J. L. Mahoney, Malaria 'breakthroughs' and resistance to chloroquine in Africa. Case  
787 reports. *S Afr Med J* **60**, 786-788 (1981).
- 788 71. A. Sette, S. Crotty, Immunological memory to SARS-CoV-2 infection and COVID-19  
789 vaccines. *Immunol Rev* **310**, 27-46 (2022).
- 790 72. M. L. Holshue *et al.*, First Case of 2019 Novel Coronavirus in the United States. *N Engl J*  
791 *Med* **382**, 929-936 (2020).
- 792 73. Y. Bai *et al.*, Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA* **323**, 1406-  
793 1407 (2020).
- 794 74. C. Rothe *et al.*, Transmission of 2019-nCoV Infection from an Asymptomatic Contact in  
795 Germany. *N Engl J Med* **382**, 970-971 (2020).
- 796 75. B. Nussbaumer-Streit *et al.*, Quarantine alone or in combination with other public health  
797 measures to control COVID-19: a rapid review. *Cochrane Database Syst Rev* **9**, CD013574  
798 (2020).
- 799 76. C. N. Chang, H. Y. Chien, L. Malagon-Palacios, College reopening and community spread  
800 of COVID-19 in the United States. *Public Health* **204**, 70-75 (2022).
- 801 77. C. R. K. Arnold *et al.*, A longitudinal study of the impact of university student return to  
802 campus on the SARS-CoV-2 seroprevalence among the community members. *Sci Rep* **12**,  
803 8586 (2022).
- 804 78. N. Bharti *et al.*, Large university with high COVID-19 incidence is not associated with  
805 excess cases in non-student population. *Sci Rep* **12**, 3313 (2022).
- 806 79. B. H. Pollock *et al.*, Safe reopening of college campuses during COVID-19: The University  
807 of California experience in Fall 2020. *PLoS One* **16**, e0258738 (2021).
- 808 80. A. W. D. Edridge *et al.*, Seasonal coronavirus protective immunity is short-lasting. *Nat Med*  
809 **26**, 1691-1693 (2020).

- 810 81. W. S. Lee, A. K. Wheatley, S. J. Kent, B. J. DeKosky, Antibody-dependent enhancement and  
811 SARS-CoV-2 vaccines and therapies. *Nat Microbiol* **5**, 1185-1191 (2020).
- 812 82. A. M. Arvin *et al.*, A perspective on potential antibody-dependent enhancement of SARS-  
813 CoV-2. *Nature* **584**, 353-363 (2020).
- 814 83. B. S. Graham, Rapid COVID-19 vaccine development. *Science* **368**, 945-946 (2020).
- 815 84. A. Iwasaki, Y. Yang, The potential danger of suboptimal antibody responses in COVID-19.  
816 *Nat Rev Immunol* **20**, 339-341 (2020).
- 817 85. J. Van Elslande *et al.*, Lower persistence of anti-nucleocapsid compared to anti-spike  
818 antibodies up to one year after SARS-CoV-2 infection. *Diagn Microbiol Infect Dis* **103**,  
819 115659 (2022).
- 820 86. K. A. Dowd, T. C. Pierson, Antibody-mediated neutralization of flaviviruses: a reductionist  
821 view. *Virology* **411**, 306-315 (2011).
- 822 87. S. F. Wang *et al.*, Antibody-dependent SARS coronavirus infection is mediated by  
823 antibodies against spike proteins. *Biochem Biophys Res Commun* **451**, 208-214 (2014).
- 824 88. Y. W. Kam *et al.*, Antibodies against trimeric S glycoprotein protect hamsters against SARS-  
825 CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells  
826 in vitro. *Vaccine* **25**, 729-740 (2007).
- 827 89. Y. Wan *et al.*, Molecular Mechanism for Antibody-Dependent Enhancement of  
828 Coronavirus Entry. *J Virol* **94**, (2020).
- 829 90. T. Takano, C. Kawakami, S. Yamada, R. Satoh, T. Hohdatsu, Antibody-dependent  
830 enhancement occurs upon re-infection with the identical serotype virus in feline  
831 infectious peritonitis virus infection. *J Vet Med Sci* **70**, 1315-1321 (2008).
- 832 91. T. Hohdatsu *et al.*, Antibody-dependent enhancement of feline infectious peritonitis virus  
833 infection in feline alveolar macrophages and human monocyte cell line U937 by serum of  
834 cats experimentally or naturally infected with feline coronavirus. *J Vet Med Sci* **60**, 49-55  
835 (1998).
- 836 92. D. Li *et al.*, In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and  
837 neutralizing antibodies. *Cell* **184**, 4203-4219 e4232 (2021).
- 838 93. Y. Liu *et al.*, An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by  
839 antibodies. *Cell* **184**, 3452-3466 e3418 (2021).
- 840 94. K. R. Bewley *et al.*, Immunological and pathological outcomes of SARS-CoV-2 challenge  
841 following formalin-inactivated vaccine in ferrets and rhesus macaques. *Sci Adv* **7**,  
842 eabg7996 (2021).
- 843 95. C. Li *et al.*, Absence of Vaccine-enhanced Disease With Unexpected Positive Protection  
844 Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated  
845 Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model. *Clin Infect Dis*  
846 **73**, e719-e734 (2021).
- 847 96. H. S. Ismanto *et al.*, Landscape of infection enhancing antibodies in COVID-19 and healthy  
848 donors. *Comput Struct Biotechnol J* **20**, 6033-6040 (2022).
- 849 97. S. Mu *et al.*, Neutralizing antibodies from the rare convalescent donors elicited antibody-  
850 dependent enhancement of SARS-CoV-2 variants infection. *Front Med (Lausanne)* **9**,  
851 952697 (2022).
- 852 98. C. Gartlan *et al.*, Vaccine-Associated Enhanced Disease and Pathogenic Human  
853 Coronaviruses. *Front Immunol* **13**, 882972 (2022).



- 854 99. M. Schafer *et al.*, Determinants of university students' COVID-19 vaccination intentions  
855 and behavior. *Sci Rep* **12**, 18067 (2022).
- 856 100. T. Dzinamarira *et al.*, Unpacking the Implications of SARS-CoV-2 Breakthrough Infections  
857 on COVID-19 Vaccination Programs. *Vaccines (Basel)* **10**, (2022).
- 858 101. A. Haque, A. B. Pant, Mitigating Covid-19 in the face of emerging virus variants,  
859 breakthrough infections and vaccine hesitancy. *J Autoimmun* **127**, 102792 (2022).
- 860 102. M. Kang *et al.*, Transmission dynamics and epidemiological characteristics of SARS-CoV-2  
861 Delta variant infections in Guangdong, China, May to June 2021. *Euro Surveill* **27**, (2022).
- 862 103. C. Fischer *et al.*, Gradual emergence followed by exponential spread of the SARS-CoV-2  
863 Omicron variant in Africa. *Science*, eadd8737 (2022).
- 864 104. R. Nutalai *et al.*, Potent cross-reactive antibodies following Omicron breakthrough in  
865 vaccinees. *Cell* **185**, 2116-2131 e2118 (2022).
- 866 105. L. Liu *et al.*, Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.  
867 *Nature* **602**, 676-681 (2022).
- 868 106. E. Cameroni *et al.*, Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron  
869 antigenic shift. *Nature* **602**, 664-670 (2022).
- 870 107. B. A. Petros *et al.*, Early introduction and rise of the Omicron SARS-CoV-2 variant in highly  
871 vaccinated university populations. *Clin Infect Dis*, (2022).
- 872 108. N. van Doremalen *et al.*, SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus  
873 macaques as compared to Delta. *Sci Adv* **8**, eade1860 (2022).
- 874 109. E. Takashita *et al.*, In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6.  
875 *N Engl J Med* **387**, 2094-2097 (2022).
- 876 110. M. Cox *et al.*, SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro  
877 studies. *Nat Rev Microbiol*, 1-13 (2022).
- 878 111. Y. J. Park *et al.*, Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.  
879 *Science* **378**, 619-627 (2022).
- 880 112. M. Hoffmann *et al.*, The Omicron variant is highly resistant against antibody-mediated  
881 neutralization: Implications for control of the COVID-19 pandemic. *Cell* **185**, 447-456 e411  
882 (2022).
- 883 113. P. Qu *et al.*, Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75  
884 variant. *Cell Host Microbe* **30**, 1518-1526 e1514 (2022).
- 885

886

887 **FIGURE LEGENDS**

888

889 **FIGURE 1. Overview of our university COVID monitoring program and workflow. (A)** Map  
890 of Ohio with locations of the six university campuses which participated in the COVID monitoring  
891 program. **(B)** On and prior to the day of testing, each individual assessed themselves for one or  
892 more COVID symptoms (see *Methods* for complete list). If symptomatic, the individual was given  
893 a clinical referral and instructed to not go to their on-campus testing facility, to prevent contagion.  
894 If asymptomatic, the individual provided a saliva sample which was tested (typically within 24  
895 hours of sample provision) via qRT-PCR for the presence of the CoV2 N gene. Individuals were  
896 notified as soon as possible as to whether their sample was negative (PCR<sup>NEG</sup>) or positive  
897 (PCR<sup>POS</sup>) for the virus, a positive result being a  $C_T \leq 40$ . PCR<sup>POS</sup> samples were subsequently  
898 aliquoted and used for both CoV2 lineage identification and measuring the concentrations of  
899 immunoglobulin against specific CoV2 antigens (CoV2-Ig). The vast majority of PCR<sup>NEG</sup> samples  
900 were discarded; however, a minority were retained and used for CoV2-Ig measurements. PCR<sup>POS</sup>  
901 and PCR<sup>NEG</sup> samples were otherwise treated identically.

902

903 **FIGURE 2. The incidence of PCR positivity among asymptomatic members of our**  
904 **university community.** Saliva samples from asymptomatic individuals were collected on a daily  
905 basis and tested by qRT-PCR for the presence of the CoV2 N gene. Shown are the number of  
906 PCR<sup>POS</sup> saliva samples identified each day during the period spanning Jan 2021 → May 2022,  
907 with each bar representing a single day. Above the graph is a timeline depicting when COVID  
908 vaccine availability shifted in Ohio (i.e. when the national vaccination priority expanded from  
909 vulnerable populations to encompass anyone >15 years of age), as well as indications of the  
910 deadlines by which all university community members were required to have received their first  
911 and second vaccine dose of either the BNT162b2 or mRNA-1273 vaccines. Below the graph are

912 indications of the periods we refer to as Waves 1-6, a wave being defined as when the daily  
913 PCR<sup>POS</sup> case count exceeded the period median (15) for  $\geq 3$  weeks, as well Blue shading indicates  
914 when the samples we used for CoV2 Ig measurements were collected.

915

916 **FIGURE 3. Saliva CoV2 viral loads among asymptomatic members of our university**

917 **community. (A)** Box plot representation of all the  $C_T$  values of all the PCR<sup>POS</sup> saliva samples

918 during each week of the period spanning Jan 2021  $\rightarrow$  Jun 2022. The blue line passes through

919 the median  $C_T$  value of each week. Below the graph are indications of the periods corresponding

920 to Waves 1-6 of the prior figure. **(B)** Scatter plot representation of the same  $C_T$  value data as in

921 **(A)** above, the exceptions being daily data are shown (as opposed to weekly composites) and

922 samples with a  $C_T > 33$  are omitted (these could not be sequenced due to insufficient amounts of

923 genetic material). Each dot represents an individual sample; the color of each diamond indicates

924 the CoV2 lineage present (Green, CoV2<sup>US</sup>; Pink, CoV2<sup>Alpha</sup>; White, CoV2<sup>Beta</sup>; Blue, CoV2<sup>Gamma</sup>;

925 Red, CoV2<sup>Delta</sup>; Gold, CoV2<sup>O-BA.1</sup>; Orange, CoV2<sup>O-BA.2</sup>). Gray diamonds indicate samples whose

926 lineage was not a VOC. Black squares indicate a sequence that did not align to known lineages

927 and thus could not be assigned. Note that CoV2<sup>Beta</sup> only appeared once in our university

928 community, on Apr 15 2021. **(C)** The  $C_T$  value and **(D)** calculated CoV2 genome copy

929 concentration in of each positive sample during Wave 1, Wave 2, Wave 3, Wave 4, Wave 5 and

930 Wave 6. The “Vax” arrow indicates when community vaccine requirements went into effect (after

931 Wave 4, before Wave 5). Asterisks indicate those inter-wave differences that were statistically

932 significant, as determined by one way ANOVA (\*  $p \leq 0.05$ , \*\*  $p \leq 0.005$ , \*\*\*  $p \leq 0.0005$ , \*\*\*  $p \leq$

933 0.00005).

934

935 **FIGURE 4. Spike-specific Ig levels in the saliva of newly positive, asymptomatic individuals**

936 **at the time of PCR testing.** Saliva samples from individuals who were newly positive (New<sup>POS</sup>,



937 PCR positive for the first time ever) for either the CoV2<sup>US</sup>, CoV2<sup>Alpha</sup>, CoV2<sup>Gamma</sup> or CoV2<sup>Delta</sup>  
938 lineage were used to measure the concentrations of (A) IgM<sup>Spike</sup>, (B) IgA<sup>Spike</sup> and (C) IgG<sup>Spike</sup>. The  
939 CoV2<sup>Anc</sup> Spike was used as the capture antigen in each case, and concentrations are expressed  
940 as World Health Organization (WHO) binding antibody units (BAU) per mL. PCR<sup>NEG</sup> saliva  
941 collected in early 2020, from healthy individuals living in the US with no COVID history, was tested  
942 in the same manner used to estimate “pre-pandemic” levels of IgM<sup>Spike</sup>, IgA<sup>Spike</sup> and IgG<sup>Spike</sup>  
943 binding, which are represented by the dashed lines on each graph. <sup>X</sup>, values that were considered  
944 outliers but are nevertheless shown for completeness and are included in all statistical group  
945 comparisons. \* p ≤ 0.05, as determined by unpaired Wilcoxon tests with Benjamini-Hochberg  
946 adjustment.

947

948 **FIGURE 5. Nucleocapsid- and Spike-specific IgG levels in saliva of newly positive,**  
949 **asymptomatic individuals versus prior positive, asymptomatic individuals.** Saliva from  
950 New<sup>POS</sup> individuals infected with either CoV2<sup>US</sup> or CoV2<sup>Alpha</sup>, as well as PCR<sup>NEG</sup> saliva from  
951 individuals who had been infected 3-9 months prior (Prior<sup>POS</sup>) with either CoV2<sup>US</sup>, CoV2<sup>Alpha</sup> or a  
952 non-VOC, were used to measure the concentrations of (A) Nucleocapsid-specific IgG, (B) Spike-  
953 specific IgG, and (C) Spike RBD-specific IgG. \* p ≤ 0.05, as determined by unpaired Wilcoxon test  
954 with Benjamini-Hochberg adjustment.

955

956 **FIGURE 6. Spike-specific Ig levels in saliva of CoV2<sup>Delta</sup>-infected unvaccinated individuals,**  
957 **CoV2<sup>Delta</sup>-infected vaccinees, and uninfected vaccinees.** During and shortly after COVID  
958 Wave 4 (i.e. that which was caused by CoV2<sup>Delta</sup>), saliva from three groups of individuals were  
959 collected and used for Ig measurements: those who had not been fully vaccinated and were  
960 positive for the CoV2<sup>Delta</sup> lineage (Vax<sup>NEG</sup>PCR<sup>POS</sup>), those who had been fully vaccinated and were  
961 positive for the CoV2<sup>Delta</sup> lineage (Vax<sup>POS</sup>PCR<sup>POS</sup>), and those who had been fully vaccinated and

962 were negative for any CoV2 lineage ( $Vax^{POS}PCR^{NEG}$ ). Shown are the (A)  $IgM^{Spike}$ , (B)  $IgA^{Spike}$  and  
963 (C)  $IgG^{Spike}$  levels in each individual sample per group. <sup>X</sup>, values that were considered outliers but  
964 are nevertheless shown for completeness and are included in all statistical group comparisons. \*  
965  $p \leq 0.05$ , as determined by unpaired Wilcoxon tests with Benjamini-Hochberg adjustment.

966

967 **FIGURE 7. Inhibition of Spike function by saliva of CoV2<sup>Delta</sup>-infected unvaccinated**  
968 **individuals, CoV2<sup>Delta</sup>-infected vaccinees, and uninfected vaccinees (A)** Depiction of the  
969 probe-conjugated ACE2 displacement assay used to measure saliva samples' ability to inhibit  
970 CoV2 Spike binding to its human receptor, ACE2. The samples in this case were from  
971  $VAX^{NEG}PCR^{POS}$ ,  $VAX^{POS}PCR^{POS}$  and  $VAX^{POS}PCR^{NEG}$  individuals (the same samples used for  
972  $IgM^{Spike}$ ,  $IgA^{Spike}$  and  $IgG^{Spike}$  measurements in **FIG 6** above). (B) The percent inhibition value of  
973 each individual sample in each group. Within the (C-E)  $VAX^{NEG}PCR^{POS}$  group, (F-H)  
974  $VAX^{POS}PCR^{POS}$  group, and (I-K)  $VAX^{POS}PCR^{NEG}$  group, the relationship between an individual  
975 samples' inhibition value and cognate (C,F,H)  $IgM^{Spike}$  concentration, (D,G,I)  $IgM^{Spike}$   
976 concentration, and (E,H,J)  $IgG^{Spike}$  concentration. Graph insets indicates the Multiple R-squared  
977 value associated with the linear regression model of the respective data set (i.e. the % variation  
978 in inhibition that can be explained by the indicated Ig concentration), as well as its p-value (i.e.  
979 the significance of the linear model as a whole).

980

981 **Supplemental FIGURE S1. The CoV2 antigens and components relevant to our study. (A)**  
982 Depiction of CoV2 and its RNA genome, nucleocapsid (N, yellow) and Spike proteins, the latter  
983 being differentially colored to indicate the Receptor Binding Domain (RBD, blue) and non-RBD  
984 regions (green). (B) The amino acids which distinguish the CoV2<sup>Anc</sup> Spike protein from CoV2<sup>US</sup>  
985 (also known as B.1.2), CoV2<sup>Alpha</sup>, CoV2<sup>Gamma</sup> and CoV2<sup>Delta</sup>, as well as the Omicron lineages  
986 CoV2<sup>O-BA.1</sup>, CoV2<sup>O-BA.2</sup>, CoV2<sup>O-BA.4</sup> and CoV2<sup>O-BA.5</sup>.

987

988 **Supplemental FIGURE S2. The waves of COVID incidence in the counties surrounding our**  
989 **university campuses.** Daily COVID cases in the counties surrounding each campus of our  
990 university, as reported by the Ohio Department of Health (ODH), for the period spanning Jan 2021  
991 → May 2022. Shown are the data for **(A)** Franklin County, which surrounds the OSU-Columbus  
992 campus; **(B)** Licking County, which surrounds the OSU-Newark campus; **(C)** Richland County,  
993 which surrounds the OSU-Mansfield campus; **(D)** Allen County, which surrounds the OSU-Lima  
994 campus; **(E)** Marion County, which surrounds the OSU-Marion campus; and **(F)** Wayne County,  
995 which surrounds the OSU-Wooster campus. Overlaid onto each graph are the dates which  
996 correspond to the six COVID waves (W1-W6) that occurred in our campus community (see **FIG**  
997 **2**).



998  
999 **Supplemental FIGURE S3. The age of individuals whose PCR<sup>POS</sup> saliva sample was viral**  
1000 **genome sequenced.** The age range of individuals whose saliva was PCR<sup>POS</sup> and sequenced  
1001 throughout the monitoring period. Violin plots depicting the ages of individuals whose saliva was  
1002 PCR<sup>POS</sup> and sequenced each month.

1003  
1004 **Supplemental FIGURE S4. The representation of each sex among individuals whose**  
1005 **PCR<sup>POS</sup> saliva met sequencing criteria.** The percent of males, females and undefined sex  
1006 among individuals whose saliva was PCR<sup>POS</sup> and sequenced for lineage identification for each  
1007 week of our study period, the criteria for sequencing being a  $C_T \leq 33$ . Overlaid onto the graph in  
1008 gray are the periods corresponding to Waves 1-6 in our university community. The average values  
1009 for each sex across the entire study period are indicated by the hatched lines.


1010  
1011 **Supplemental FIGURE S5. VOC Spike-specific Ig levels in the saliva of newly positive,**  
1012 **asymptomatic individuals at the time of PCR testing.** Saliva samples that were positive for

1013 either the CoV2<sup>US</sup>, CoV2<sup>Alpha</sup>, CoV2<sup>Gamma</sup> or CoV2<sup>Delta</sup> lineage were used to measure the  
1014 concentrations of (A) IgM<sup>Spike</sup>, (B) IgA<sup>Spike</sup> and (C) IgG<sup>Spike</sup>. Varying by column were the coating  
1015 antigens (Ag) used for each measurement, the Ag being recombinant forms of either the CoV<sup>Anc</sup>  
1016 Spike (Column 1), CoV2<sup>Alpha</sup> Spike (Column 2), CoV2<sup>Beta</sup> Spike (Column 3), and CoV2<sup>Gamma</sup> Spike  
1017 (Column 4). Antibody levels are expressed in arbitrary units of luminescence. Note that the CoV<sup>Anc</sup>  
1018 -specific IgM, IgA and IgG values in (A-C) Column 1 were transformed into WHO Binding Antibody  
1019 Units (BAUs) for **FIG 4**.





1020  
1021 **Supplemental FIGURE S6. VOC Spike-specific Ig levels in saliva of CoV2<sup>Delta</sup>-infected**  
1022 **unvaccinated individuals, CoV2<sup>Delta</sup>-infected vaccinees, and uninfected vaccinees.** During  
1023 and after COVID Wave 4 (i.e. that which was caused by CoV2<sup>Delta</sup>), saliva from three groups of  
1024 individuals were collected and used for Ig measurements: those who had not been fully  
1025 vaccinated and were positive for CoV2<sup>Delta</sup> (Vax<sup>NEG</sup> PCR<sup>POS</sup>), those who had been fully vaccinated  
1026 and were positive for the CoV2<sup>Delta</sup> (Vax<sup>POS</sup> PCR<sup>POS</sup>), and those who had been fully vaccinated  
1027 and were negative for any CoV2 lineage (Vax<sup>POS</sup> PCR<sup>NEG</sup>). Shown for each individual in each  
1028 group are the levels of (A) IgM<sup>Spike</sup>, (B) IgA<sup>Spike</sup> and (C) IgG<sup>Spike</sup> which bind to four different coating  
1029 antigens (Ag), the Ag being recombinant forms of either the CoV<sup>Anc</sup> Spike (Column 1), CoV2<sup>Alpha</sup>  
1030 Spike (Column 2), CoV2<sup>Beta</sup> Spike (Column 3), CoV2<sup>Gamma</sup> Spike (Column 4) and CoV2<sup>Delta</sup> Spike  
1031 (Column 5). Antibody levels are expressed in arbitrary units of luminescence. Note that the CoV<sup>Anc</sup>  
1032 -specific IgM, IgA and IgG values in (A-C) Column 1 were transformed into WHO Binding Antibody  
1033 Units (BAUs) for **FIG 6**.



**FIGURE 1**




**FIGURE 2**






**FIGURE 3**









**FIGURE 4**



**FIGURE 5**




**FIGURE 6**




**FIGURE 7**







A




B




Supplemental FIGURE S1











**Supplemental FIGURE S3**





Supplemental FIGURE S4





**Supplemental FIGURE S6**